VEGFA and female reproductive organ cancer: Bevacizumab, a novel anticancer agent used widely in cases of gynecologic cancer, is a monoclonal antibody that targets vascular endothelial growth factor and has proven efficacy in platinum-resistant ovarian cancer, when administered as a single agent and in combination with cytotoxic chemotherapy [21–24].